

AMENDMENTS

Please enter the following amendments.

In the specification

Page 1, line 9, please delete the text under "Cross-Reference to Related Applications" and substitute

Page 1
C1
--This application is in the U.S. National Phase of international application PCT/US96/20757, filed December 19, 1996, which claims priority to U.S. Serial No. 08/766,350, filed December 13, 1996, which claims the priority benefit to provisional application serial no. 60/035,345 (converted from U.S. Serial No. 08/591,965), filed January 29, 1996, all of which are incorporated by reference in their entirety.

Page 8, line 28, please delete "12303 Parklawn Drive, Rockville, MD, U.S.A. 20852" and insert --10801 University Boulevard, Manassas, VA 20110-2209--;

Page 8, line 32, after "number" (first instance), please insert --60/031,306--; and

Page 46, line 29, after "No.", please insert --60/031,306--.

In the claims

cancel
2 Please cancel claim 13 without prejudice or disclaimer.

C2
Pro
4
6. (Amended) A[n isolated] polynucleotide comprising a sequence encoding a polypeptide [having immunological activity of monoclonal anti-idiotypic antibody 11D10] that is capable of eliciting an anti-HMFG immunological response in a mammal, wherein the polypeptide comprises [at least 5 contiguous amino acids of a variable region of 11D10] an immunoglobulin variable region containing the three light chain complementarity determining regions (CDRs) of antibody 11D10 or an immunoglobulin variable region containing the three heavy chain CDRs of antibody 11D10, wherein antibody 11D10 is produced by the hybridoma deposited under ATCC Accession No. HB-12020 or progeny thereof.